Tanja M Gampfer

Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany. Electronic address: tanja.gampfer@uks.eu.

2 papers in the library · 12 citations · publishing 2024-2025

Papers

Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assay.

Journal of pharmaceutical and biomedical analysis August 1, 2024 Tanja M Gampfer, Victoria Schütz, Philip Schippers et al. 11 citations

Two new hallucinogenic drugs, 1cP-LSD and 4-AcO-DET, were metabolized in human liver S9 fraction and in zebrafish larvae, with several phase I and phase II metabolites identified. Some metabolites were unique to zebrafish larvae. Neither compound showed toxic effects on human liver cells, though 4-AcO-DET combined with a CYP inhibitor altered two cellular parameters at concentrations far above expected in vivo levels. The authors suggest further testing with other liver cell lines that express more CYP enzymes.

DOI: 10.1016/j.jpba.2024.116187 Full text Cytotoxicity Hepg2 Lc-hrms/ms New psychoactive substances +5

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing.

British journal of clinical pharmacology June 16, 2025 Wellenberg K Simon, Tanja M Gampfer, Wagmann Lea et al. 1 citation

A workflow using zebrafish embryos (ZEs) followed by human microdosing (HMD) can identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB-CHMICA, and MDPPP were first identified in ZEs exposed via immersion or injection, then compared with known human metabolites and confirmed by HMD. Both methods identified main human urine metabolites, except for LSD (due to low dose) and cannabinoids (due to low oral bioavailability). ZEs produced more metabolites, including conjugates, than HMD. The approach provides quick, reliable data for urinary drug screening, though challenges remain with HMD, including different administration routes and low-dose detectability.

DOI: 10.1002/bcp.70140 Full text Microdosing Lc‐hrms/ms Drugs of abuse New psychoactive substances +15